Report Overview

The Brazil Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market size stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Non-small Cell Lung Cancer is the most common type of lung cancer with an incidence rate of approximately 85% of the total lung cancer cases. The primary risk factors associated with the NSCLC are excessive active smoking, excessive passive smoking, and high levels of exposure to air pollution and consumption of contaminated water. There have been numerous breakthrough developments in the NSCLC treatment which have played an instrumental role in increasing the survival rate of the diagnosed patients.



Market Drivers

An increasing number of diagnoses of non-small cell lung cancer and the increasing awareness in the country due to Brazilian governments initiative is also contributing towards the non-small cell lung cancer therapeutics market growth. This, coupled with increasing investments by major players in research and development activities, and the inclusion of non-small cell cancer therapeutics in pipelines of major market players are also boosting the market growth.

Some of the other factors which are also contributing to the non-small cell lung cancer therapeutics market growth are the increase in the proportion of the smoking population, unhealthy lifestyles of people and exposure to toxins such as asbestos.